ES3060954T3 - The 5ht agonist clemizole for use in treating epilepsy disorders - Google Patents

The 5ht agonist clemizole for use in treating epilepsy disorders

Info

Publication number
ES3060954T3
ES3060954T3 ES22157142T ES22157142T ES3060954T3 ES 3060954 T3 ES3060954 T3 ES 3060954T3 ES 22157142 T ES22157142 T ES 22157142T ES 22157142 T ES22157142 T ES 22157142T ES 3060954 T3 ES3060954 T3 ES 3060954T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
clemizole
acceptable salt
administered
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22157142T
Other languages
English (en)
Spanish (es)
Inventor
Scott Baraban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES3060954T3 publication Critical patent/ES3060954T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES22157142T 2015-02-25 2016-02-24 The 5ht agonist clemizole for use in treating epilepsy disorders Active ES3060954T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25

Publications (1)

Publication Number Publication Date
ES3060954T3 true ES3060954T3 (en) 2026-03-30

Family

ID=56789223

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22157142T Active ES3060954T3 (en) 2015-02-25 2016-02-24 The 5ht agonist clemizole for use in treating epilepsy disorders
ES16756282T Active ES2920886T3 (es) 2015-02-25 2016-02-24 Agonistas de 5HT para el tratamiento de trastornos epilépticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16756282T Active ES2920886T3 (es) 2015-02-25 2016-02-24 Agonistas de 5HT para el tratamiento de trastornos epilépticos

Country Status (21)

Country Link
US (5) US10874643B2 (https=)
EP (4) EP4696377A3 (https=)
JP (5) JP6884703B2 (https=)
KR (3) KR102385665B1 (https=)
CN (2) CN113546174A (https=)
AU (3) AU2016222804C1 (https=)
BR (1) BR112017018297B1 (https=)
CA (2) CA3204599A1 (https=)
CY (1) CY1125360T1 (https=)
DK (1) DK3261640T3 (https=)
EA (2) EA201992474A3 (https=)
ES (2) ES3060954T3 (https=)
HR (1) HRP20220822T1 (https=)
HU (1) HUE059559T2 (https=)
LT (1) LT3261640T (https=)
PL (1) PL3261640T3 (https=)
PT (1) PT3261640T (https=)
RS (1) RS63426B1 (https=)
SI (1) SI3261640T1 (https=)
SM (1) SMT202200276T1 (https=)
WO (1) WO2016138138A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12268683B2 (en) 2018-07-18 2025-04-08 The Regents Of The University Of California Compounds and methods for synergistic activation of M channels
JP2021530541A (ja) * 2018-07-27 2021-11-11 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. てんかんの治療方法
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
WO2020243349A1 (en) * 2019-05-29 2020-12-03 The Regents Of The University Of California Methods and compositions for treating epilepsy
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
CN120267677A (zh) * 2019-10-23 2025-07-08 纽罗塞克医疗公司 用gabaa受体调节剂的癫痫状况的治疗
ES3056138T3 (en) * 2019-10-23 2026-02-18 Maplight Therapeutics Inc Methods of treating the symptoms of autism spectrum disorder
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2021113834A1 (en) * 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20240189240A1 (en) * 2021-03-25 2024-06-13 Maplight Therapeutics, Inc. Pharmaceutical compositions comprising zolmitriptan
EP4346804A4 (en) * 2021-06-01 2025-05-07 Arena Pharmaceuticals, Inc. TREATMENT PROCEDURES
JP2024521399A (ja) * 2021-06-10 2024-05-31 ニューレリス、インク． 小児患者における発作性障害を治療するための組成物および方法
JP2024529509A (ja) * 2021-07-30 2024-08-06 エピジェニクス セラピューティクス インコーポレーテッド クレミゾール製剤
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
US20250295611A1 (en) * 2022-04-27 2025-09-25 Tessellate Therapeutics Inc. Methods of treating 5ht2a receptor-mediated conditions
IL315086A (en) 2022-06-09 2024-10-01 Diamond Therapeutics Inc Amorphous (A-polymorphic) psilocybin
WO2024118280A1 (en) * 2022-11-30 2024-06-06 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action
CN119564685B (zh) * 2024-12-16 2026-02-06 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
WO2005032329A2 (en) 2003-08-22 2005-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20050215589A1 (en) * 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008036586A2 (en) 2006-09-20 2008-03-27 Waters Investments Limited Apparatus and methods of fluid chromatography
KR101475248B1 (ko) 2007-04-06 2014-12-22 코닌클리케 필립스 엔.브이. 공기 오염 센서 시스템
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
EP2152276A4 (en) 2007-05-09 2011-09-14 Traffick Therapeutics Inc SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING
JP5715820B2 (ja) 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
KR20100137473A (ko) * 2008-02-19 2010-12-30 아돌로 코포레이션 동통 치료를 위한 벨록세핀, 이의 거울상이성질체, 및 이의 유사체
JP2011518154A (ja) 2008-04-16 2011-06-23 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−１−｛２−［４’−（３−メトキシプロパン−１−スルホニル）−ビフェニル−４−イル］−エチル｝−２−メチル−ピロリジンの合成に有用なプロセス
CN102088990A (zh) 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
US20110217265A1 (en) 2008-09-23 2011-09-08 Glenn Jeffrey S Screening for Inhibitors of HCV Amphipathic Helix (AH) Function
EP2408448A4 (en) 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
JP5656980B2 (ja) 2009-05-13 2015-01-21 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー含有の置換芳香族トリアジン化合物
CN102666537A (zh) 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015096119A1 (zh) 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
ES2920886T3 (es) 2022-08-11
AU2022203274B2 (en) 2024-08-15
CN107530326B (zh) 2021-09-21
EP4043016B1 (en) 2025-10-29
AU2016222804C1 (en) 2021-10-14
DK3261640T3 (da) 2022-07-11
JP2020143087A (ja) 2020-09-10
AU2021204261B2 (en) 2023-08-10
RS63426B1 (sr) 2022-08-31
EP3261640B1 (en) 2022-04-06
US20200147048A1 (en) 2020-05-14
JP6884703B2 (ja) 2021-06-09
US20210154171A1 (en) 2021-05-27
AU2016222804B2 (en) 2021-07-15
CN113546174A (zh) 2021-10-26
EA201992474A2 (ru) 2020-02-28
CA2977135A1 (en) 2016-09-01
JP2018506555A (ja) 2018-03-08
LT3261640T (lt) 2022-07-11
BR112017018297A2 (pt) 2018-04-17
SMT202200276T1 (it) 2022-09-14
EP4696377A2 (en) 2026-02-18
WO2016138138A1 (en) 2016-09-01
EP4696377A3 (en) 2026-04-29
EA201992474A3 (ru) 2020-05-31
CN107530326A (zh) 2018-01-02
HRP20220822T1 (hr) 2022-10-28
KR102385665B1 (ko) 2022-04-14
EP3632434A1 (en) 2020-04-08
US11648237B2 (en) 2023-05-16
EP3261640A4 (en) 2018-12-19
KR20230152844A (ko) 2023-11-03
JP2024009839A (ja) 2024-01-23
EA201791882A1 (ru) 2018-02-28
CY1125360T1 (el) 2025-05-09
JP2021185148A (ja) 2021-12-09
JP7846506B2 (ja) 2026-04-15
US10874643B2 (en) 2020-12-29
SI3261640T1 (sl) 2022-10-28
US20180028499A1 (en) 2018-02-01
PL3261640T3 (pl) 2022-10-31
HUE059559T2 (hu) 2022-12-28
AU2021204261A1 (en) 2021-07-29
KR20220048045A (ko) 2022-04-19
EP3261640A1 (en) 2018-01-03
BR112017018297B1 (pt) 2023-12-05
EP4043016A1 (en) 2022-08-17
KR20170118870A (ko) 2017-10-25
US12447144B2 (en) 2025-10-21
JP2022116307A (ja) 2022-08-09
CA2977135C (en) 2023-08-22
AU2016222804A1 (en) 2017-08-31
US20260083706A1 (en) 2026-03-26
US20230346750A1 (en) 2023-11-02
AU2022203274A1 (en) 2022-06-16
CA3204599A1 (en) 2016-09-01
PT3261640T (pt) 2022-07-06

Similar Documents

Publication Publication Date Title
ES3060954T3 (en) The 5ht agonist clemizole for use in treating epilepsy disorders
US11291653B2 (en) Compounds and methods for treating an epileptic disorder
HK40079848A (en) The 5ht agonist clemizole for use in treating epilepsy disorders
EA046651B1 (ru) Агонисты 5ht для лечения нарушений
HK40016257A (en) Compounds and methods for treating an epileptic disorder
EA040818B1 (ru) Способ лечения эпилептического расстройства с помощью агониста рецептора 5ht